Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?

Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?

To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent...

Full description

Bibliographic Details
Main Authors: Elia Bari, Ilaria Ferrarotti, Laura Saracino, Sara Perteghella, Maria Luisa Torre, Luca Richeldi, Angelo Guido Corsico
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cells
Subjects:
SARS-CoV-2
COVID-19
pulmonary fibrosis
mesenchymal stem cells
extracellular vesicles
microvesicles
Online Access:https://www.mdpi.com/2073-4409/10/5/1203
id doaj-8947104363fd421c8292bf09e3a84694
record_format Article
spelling doaj-8947104363fd421c8292bf09e3a846942021-06-01T00:01:27ZengMDPI AGCells2073-44092021-05-01101203120310.3390/cells10051203Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?Elia Bari0Ilaria Ferrarotti1Laura Saracino2Sara Perteghella3Maria Luisa Torre4Luca Richeldi5Angelo Guido Corsico6Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, ItalyCenter for Diagnosis of Inherited Alpha1-Antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, ItalyPneumology Unit IRCCS San Matteo Hospital Foundation, 27100 Pavia, ItalyDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, ItalyDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, ItalyComplex Operative Unit of Pneumology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, 00168 Rome, ItalyCenter for Diagnosis of Inherited Alpha1-Antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, ItalyTo date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors.https://www.mdpi.com/2073-4409/10/5/1203SARS-CoV-2COVID-19pulmonary fibrosismesenchymal stem cellsextracellular vesiclesmicrovesicles
collection DOAJ
language English
format Article
sources DOAJ
author Elia Bari
Ilaria Ferrarotti
Laura Saracino
Sara Perteghella
Maria Luisa Torre
Luca Richeldi
Angelo Guido Corsico
spellingShingle Elia Bari
Ilaria Ferrarotti
Laura Saracino
Sara Perteghella
Maria Luisa Torre
Luca Richeldi
Angelo Guido Corsico
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
Cells
SARS-CoV-2
COVID-19
pulmonary fibrosis
mesenchymal stem cells
extracellular vesicles
microvesicles
author_facet Elia Bari
Ilaria Ferrarotti
Laura Saracino
Sara Perteghella
Maria Luisa Torre
Luca Richeldi
Angelo Guido Corsico
author_sort Elia Bari
title Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
title_short Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
title_full Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
title_fullStr Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
title_full_unstemmed Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
title_sort mesenchymal stromal cell secretome for post-covid-19 pulmonary fibrosis: a new therapy to treat the long-term lung sequelae?
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-05-01
description To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors.
topic SARS-CoV-2
COVID-19
pulmonary fibrosis
mesenchymal stem cells
extracellular vesicles
microvesicles
url https://www.mdpi.com/2073-4409/10/5/1203
work_keys_str_mv AT eliabari mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
AT ilariaferrarotti mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
AT laurasaracino mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
AT saraperteghella mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
AT marialuisatorre mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
AT lucaricheldi mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
AT angeloguidocorsico mesenchymalstromalcellsecretomeforpostcovid19pulmonaryfibrosisanewtherapytotreatthelongtermlungsequelae
_version_ 1721416013870792704

Similar Items